Biotech News
Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission Package Anticipated in Q4 2026; Tanruprubart EU MAA Currently Under Review Vonaprument ARCHER II Phase
